Harrow (NASDAQ:HROW) Price Target Raised to $70.00

Harrow (NASDAQ:HROW) had its target price raised by stock analysts at HC Wainwright from $69.00 to $70.00 in a report released on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 81.35% from the company’s current price.

Other equities analysts have also issued research reports about the company. Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a research note on Thursday, January 22nd. Cantor Fitzgerald reissued an “overweight” rating and set a $94.00 target price on shares of Harrow in a report on Tuesday, November 11th. LADENBURG THALM/SH SH boosted their target price on shares of Harrow from $64.00 to $66.00 and gave the company a “buy” rating in a research report on Wednesday, November 12th. William Blair reaffirmed an “outperform” rating on shares of Harrow in a research report on Tuesday. Finally, Zacks Research cut Harrow from a “strong-buy” rating to a “hold” rating in a report on Monday, February 2nd. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Harrow has an average rating of “Moderate Buy” and an average price target of $71.14.

Harrow Stock Down 28.0%

Shares of HROW stock opened at $38.60 on Wednesday. The stock’s fifty day moving average price is $48.41 and its 200 day moving average price is $43.79. The company has a debt-to-equity ratio of 5.21, a current ratio of 2.72 and a quick ratio of 2.52. Harrow has a 1-year low of $20.85 and a 1-year high of $54.85. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -227.05 and a beta of 0.05.

Harrow (NASDAQ:HROW) last released its earnings results on Monday, March 2nd. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.40 by ($0.23). The company had revenue of $89.09 million for the quarter, compared to analysts’ expectations of $88.42 million. Harrow had a positive return on equity of 36.76% and a negative net margin of 1.89%. On average, research analysts expect that Harrow will post -0.53 earnings per share for the current fiscal year.

Institutional Trading of Harrow

A number of institutional investors and hedge funds have recently made changes to their positions in HROW. Royal Bank of Canada lifted its position in shares of Harrow by 102.5% during the 1st quarter. Royal Bank of Canada now owns 9,813 shares of the company’s stock valued at $261,000 after buying an additional 4,967 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Harrow by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company’s stock worth $483,000 after acquiring an additional 790 shares in the last quarter. Strs Ohio purchased a new stake in Harrow in the 1st quarter worth $149,000. Teacher Retirement System of Texas raised its position in Harrow by 4.1% during the second quarter. Teacher Retirement System of Texas now owns 8,478 shares of the company’s stock worth $259,000 after acquiring an additional 332 shares during the period. Finally, Los Angeles Capital Management LLC lifted its holdings in Harrow by 68.0% during the second quarter. Los Angeles Capital Management LLC now owns 28,779 shares of the company’s stock valued at $879,000 after purchasing an additional 11,650 shares in the last quarter. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Harrow

Here are the key news stories impacting Harrow this week:

• Positive Sentiment: Record revenue, margin progress and cash generation: Harrow reported Q4 revenue of $89.1M (33% YoY) and full‑year 2025 revenue of $272.3M (36% YoY); adjusted EBITDA rose to $61.9M for 2025 and operating cash flow turned positive ($43.9M). These fundamentals support longer‑term growth prospects. Q4 Results
• Positive Sentiment: Clinical progress: the FDA cleared an IND to support a planned Phase 3 trial for TRIESENCE to expand its label for post‑cataract inflammation and pain — a successful program could add a higher‑value indication. Phase 3 IND
• Positive Sentiment: Investor outreach: management will present at Leerink Partner’s Global Healthcare Conference (Mar 10), offering an opportunity to clarify strategy and guidance execution. Conference Presentation
• Neutral Sentiment: Full Q4 earnings call and slide deck are available for deeper inspection of unit trends (product mix, ImprimisRx shift toward higher‑margin items) and management commentary. Investors should review the transcript/slides for details. Earnings Call Transcript
• Negative Sentiment: EPS miss and mixed metrics: Harrow’s reported EPS missed consensus (company reported an EPS shortfall vs. expectations) even as revenue broadly met estimates — the profit miss is weighing on sentiment. Earnings Miss
• Negative Sentiment: FY2026 revenue guidance of $350M–$365M and Adjusted EBITDA $80M–$100M came in well below the consensus (~$394M), signaling growth that management expects to be back‑loaded; markets view the guidance shortfall as the primary near‑term negative driver. Guidance
• Negative Sentiment: Analyst downgrade and leverage concerns: a Seeking Alpha note downgraded HROW to “Sell,” highlighting persistent low margins, high leverage and rising interest expense that could constrain cash flow if growth is costly — contributing to downside pressure. Analyst Downgrade

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.